From: Analysis of the factors motivating HCV-infected patients to accept interferon therapy
Characteristics | n | % | |
---|---|---|---|
Sex | male / female | 36/58 | |
Age | (mean ± SD), years | 57.01 ± 11.55 | |
Age groups | 20-29 years | 3 | 3.19% |
30-39 years | 5 | 5.32% | |
40-49 years | 15 | 15.96% | |
50-59 years | 22 | 23.40% | |
60-69 years | 38 | 40.43% | |
70-79 years | 11 | 11.70% | |
Employment | unemployed | 42 | 44.68% |
employed | 52 | 55.32% | |
Diagnosis of liver disease | AH-C | 1 | 1.06% |
CH-C (after HCC treatment) | 87 (5) | 92.55% | |
LC-C (after HCC treatment) | 6 (4) | 6.38% | |
IFN therapy | IFN beta monotherapy | 1 | 1.06% |
IFN beta induction therapy followed Peg-IFN alpha 2b/RBV | 12 | 12.77% | |
Peg-IFN alpha 2b/RBV | 60 | 63.83% | |
Peg-IFN alpha 2a/RBV | 11 | 11.70% | |
Peg-IFN alpha 2a monotherapy | 7 | 7.45% | |
Peg-IFN alpha 2b/RBV → Peg-IFN alpha 2a monotherapy | 2 | 2.13% | |
Peg-IFN alpha 2b/RBV → Peg-IFN alpha 2a monotherapy → Peg-IFN alpha 2a/RBV | 1 | 1.06% |